Sales and Marketing

Showing 15 posts of 11526 posts found.

Pfizer: Annual COVID shots preferable to frequent boosters

January 24, 2022 Sales and Marketing

Pfizer CEO Albert Bourla has commented that an annual COVID-19 vaccine would be preferable to more frequent booster shots in …

NICE expands guidance for lokelma in adult patients with persistent hyperkalaemia

January 24, 2022 Sales and Marketing

NICE have updated the Technology Appraisal Guidance (TAG) for Lokelma (sodium zirconium cyclosilicate SZC) in the treatment of adult patients …

Veklury obtains FDA approval for COVID-19 outpatients

January 24, 2022 Sales and Marketing

The FDA has granted expedited approval of a supplemental new drug application (sNDA) for Veklury (remdesivir) for he treatment of …

Neurimmune and Ono Pharmaceutical collaborate to research neurodegenerative diseases

January 17, 2022 Sales and Marketing

Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical. The companies aim to focus on creating …

NICE draft guidance recommends new treatment for rare liver condition

January 17, 2022 Sales and Marketing

On Friday 14 January, NICE published a final draft Highly Specialised Technologies guidance, recommending odevixibat in line with its marketing …

FDA places Alzheimer’s therapeutic IND Application on hold

January 17, 2022 Sales and Marketing

The FDA has placed a hold on the Investigational New Drug (IND) application for DNL919, indicating they will provide an …

COVID-19 self-isolation cut to five full days in England

January 17, 2022 Sales and Marketing

The minimum self-isolation period for people testing positive for COVID-19 in England has been cut from seven days to five …

Trial finds new CAR T-cell therapy is effective at killing cancer cells

January 10, 2022 Sales and Marketing

A Phase I clinical trial funded by the NIHR Invention for Innovation (i4i) programme, and supported by the NIHR UCLH …

European Commission approves Lumykras for lung cancer patients

January 10, 2022 Sales and Marketing

The European Commission (EC) has granted conditional marketing authorisation for Lyumykras (sotorasib), a first-in-class KRAS inhibitor, for the treatment of …

FDA approval of QUVIVIQ (daridorexant) for the treatment of insomnia

January 10, 2022 Sales and Marketing

Idorsia Ltd has announced the FDA approval of QUVIVIQâ„¢ (daridorexant) 25 mg and 50 mg for the treatment of adult …

Phase III trial into lebrikizumab shows positive results for atopic dermatitis patients

January 10, 2022 Sales and Marketing

Almirall has reported positive results from their Phase III trial into lebrikizumab, which demonstrated significant improvement and itch relief when …

Positive CHMP opinion for sickle cell disease anaemia tablet

December 20, 2021 Sales and Marketing

Global Blood Therapeutics (GBT) have announced the CHMP adopted a positive opinion recommending marketing authorisation for Oxbryta®  (vocelotor) tablets. Oxbryta …

FDA approval of Tezspire for severe asthma

December 20, 2021 Sales and Marketing

Tezpire (tezepelumab-ekko), manufactured by AstraZeneca and Amgen, has been approved in the US for the add-on maintenance treatment of adult …

Study reveals potential link between COVID-19 and Parkinson’s Disease

December 20, 2021 Sales and Marketing

Scientists in The Netherlands have detailed a possible correlation between COVID-19 and the onset of Parkinson’s disease. The findings may …

New COVID-19 drug Sotrovimab becomes available on NHS

December 20, 2021 Sales and Marketing

Sotrovimab, commercially known as Xevudy, is now available on the NHS to reduce the risk of vulnerable patients needing hospitalisation …
The Gateway to Local Adoption Series

Latest content